AU2002335027A1 - Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors - Google Patents

Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors

Info

Publication number
AU2002335027A1
AU2002335027A1 AU2002335027A AU2002335027A AU2002335027A1 AU 2002335027 A1 AU2002335027 A1 AU 2002335027A1 AU 2002335027 A AU2002335027 A AU 2002335027A AU 2002335027 A AU2002335027 A AU 2002335027A AU 2002335027 A1 AU2002335027 A1 AU 2002335027A1
Authority
AU
Australia
Prior art keywords
tnf
alpha
treatment
casein kinase
mediated disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002335027A
Inventor
Wendy Fantl
Peng Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2002335027A1 publication Critical patent/AU2002335027A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002335027A 2002-10-15 2002-10-15 Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors Abandoned AU2002335027A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/032866 WO2004035076A1 (en) 2002-10-15 2002-10-15 Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors

Publications (1)

Publication Number Publication Date
AU2002335027A1 true AU2002335027A1 (en) 2004-05-04

Family

ID=32105944

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002335027A Abandoned AU2002335027A1 (en) 2002-10-15 2002-10-15 Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors

Country Status (2)

Country Link
AU (1) AU2002335027A1 (en)
WO (1) WO2004035076A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8586801A1 (en) 2002-10-31 2005-02-04 Pfizer HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
EP1756103A2 (en) 2004-04-26 2007-02-28 Pfizer, Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
CA2563761C (en) 2004-04-26 2009-12-29 Pfizer Inc. Inhibitors of the hiv integrase enzyme
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
US9801853B2 (en) 2010-04-06 2017-10-31 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells
US9273317B2 (en) 2011-08-09 2016-03-01 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells
WO2015077602A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating and monitoring cancers
WO2020049190A1 (en) * 2018-09-09 2020-03-12 Qanatpharma Gmbh Use of casein kinase 1 inhibitors for treating vascular diseases
EP3852742A1 (en) * 2018-09-18 2021-07-28 Société des Produits Nestlé S.A. Raf-1 kinase inhibitor compounds for skeletal muscle modulation, methods and uses thereof

Also Published As

Publication number Publication date
WO2004035076A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
AU2003282891A1 (en) Novel tyrosine kinases inhibitors
AU2003286567A1 (en) Methods for the treatment of skin disorders
EP1511730B8 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
HK1078858A1 (en) Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
HK1072545A1 (en) Novel inhibitors of kinases
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
AU2003245555A1 (en) Sphingosine kinase inhibitors
AU2003282976A1 (en) Inhibitors of glycogen synthase kinase 3
AU2003275282A1 (en) Novel tyrosine kinase inhibitors
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2003242860A1 (en) 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders
AU2002953255A0 (en) Protein kinase inhibitors
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2003291719A1 (en) Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
AU2002335027A1 (en) Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors
AU2003268424A1 (en) Treatment of pain by inhibition of p38 map kinase
AU2003260489A1 (en) Treatment of neurological disorders by dsrna adminitration
AU2003268464A1 (en) INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
AUPS251502A0 (en) Protein kinase inhibitors
AUPS251402A0 (en) Kinase inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase